Fuse Medical announced initial launch of FuseChoice™ and FuseChoice Plus Amniotic & Umbilical Membranes, and FuseChoice Plus Amniotic Joint Cushioning Fluid.
Additional launches within 1H21 will include FusePure Demineralized Bone Matrix, Strips and Cubes, and FuseTrilogy Viable Bone Matrix, an osteoconductive, osteoinductive and osteogenic DMSO-free bone void filler requiring no mixing preparation.
FuseChoice Single Layer Amniotic Membrane, FuseChoice Plus Multi-Layer Amniotic Membrane and FuseChoice Max Umbilical Membrane can be used as an anatomical barrier in a variety of clinical applications. Amniotic tissues can help provide mechanical protection to damaged tissue, while the proprietary process retains essential nutrient-rich growth factors. The FuseChoice Plus AF Amniotic Joint Cushioning Fluid is a natural liquid matrix allograft.
“We are excited about the expansion of our biologic & regenerative product portfolio. The U.S. commercialization of the FuseChoice line of products further demonstrates our belief in the future of biologics,” said Christopher C. Reeg, Chief Executive Officer of Fuse. “The FuseChoice amniotic technology provides surgeons with advanced treatment options for their patients requiring biologics intervention or use in conjunction with surgery.”